Novavax says its COVID-19 vaccine is more than 90-pecent effective in a late-stage clinical trial.
The study was conducted on nearly 30-thousand volunteers in the U.S. and Mexico, showing overall efficacy of 90.4 percent.
The vaccine was also shown to be 93-percent effective against variants.
It also found the vaccine was 100-percent effective in preventing moderate and severe cases of the virus.
South Korea has so far secured 40 million Novovax doses, and will get up to 20 million more within the third quarter.